STM JOURNALS

International Journal of
Membranes

Volume 1, Issue 2, 2024
July—December
DOI (Journal): 10.37591/IJM

https://journals.stmjournals.com/ijm

Review IJM

Evaluation of Polysaccharide-Based Membranes for Transdermal Drug Delivery in Chronic Pain Management

Priyanshu Upadhyay[1,*]

Abstract

In order to improve treatment effectiveness and patient compliance, chronic pain management is still a major challenge in modern healthcare, requiring creative medication delivery methods. The potential of polysaccharide-based membranes for transdermal drug delivery is assessed in this work, with particular attention to chitosan, alginate, and hydroxypropyl methylcellulose. Fourier-transform infrared spectroscopy and scanning electron microscopy were two characterization techniques used to assess the membranes' physical and chemical properties. The kinetics of diclofenac sodium release was investigated in vitro. The results showed that alginate membranes produced an initial burst effect, but chitosan membranes offered a sustained release profile. Superior drug flux via alginate membranes was shown in penetration assays, suggesting that alginate membranes have a quick therapeutic effect. All membrane types were found to be safe through biocompatibility testing, with chitosan exhibiting the highest cell viability. The findings imply that polysaccharide-based membranes, in particular chitosan and alginate, are viable options for efficient transdermal drug delivery systems intended to treat chronic pain, which calls for more research into clinical applications and formulation optimization.

Keywords: Hydropropyl methylcellulose (HPMC), polysaccharide membranes, biocompatibility, drug release kinetics, sustained release, pain alleviation, formulation optimization, pharmaceutical applications, in vitro studies, effectiveness of treatment.

INTRODUCTION

Background on Chronic Pain and Its Global Impact

Chronic pain is a persistent, often debilitating condition affecting millions globally, characterized by its duration (typically more than three months) and the significant impact it has on patients' quality of life [1]. Common sources include musculoskeletal issues like arthritis, neuropathic disorders, and other chronic health conditions. Chronic pain can lead to various physical, emotional, and socioeconomic challenges, including reduced mobility, depression, and even job loss. Current estimates indicate that about 20–30% of the global population suffers from chronic pain, making it a major public health issue [2].

*Author for Correspondence
Priyanshu Upadhyay
E-mail: priyanshu.upadhyay651@gmail.com

[1]Student, Department of Pharmacy, P.K. University, Shivpuri, Madhya Pradesh, India.

Received date: October 27, 2024
Accepted date: October 29, 2024
Published date: November 12, 2024

Citation: Priyanshu Upadhyay. Evaluation of Polysaccharide-Based Membranes for Transdermal Drug Delivery in Chronic Pain Management. International Journal of Membranes. 2024; 1(2): 28–38p.

Common Treatments and Their Limitations

In order to manage chronic pain, analgesics, such as opioids, non-steroidal anti-inflammatory medications (NSAIDs), and adjuvant treatments like antidepressants or anticonvulsants are usually used [3]. However, these treatments come with notable limitations:

- *Side effects:* Long-term NSAID use can lead to gastrointestinal issues, cardiovascular risks, and kidney damage [1].
- *Risk of dependency:* Opioids, while effective, pose a high risk of addiction, tolerance,

and overdose, leading to a significant societal impact, particularly in countries facing an opioid crisis.
- *Poor compliance:* Due to side effects, complex dosing schedules, and pill fatigue, patient adherence can be low, resulting in suboptimal pain control [4].

Transdermal Drug Delivery Systems (TDDS) for Pain Management

TDDS have become a useful substitute for injectable and oral methods, especially when it comes to managing chronic pain [3]. TDDS administers drugs through the skin, offering a controlled and sustained release directly into the systemic circulation [1]. This approach provides several distinct advantages:
- *Avoidance of first-pass metabolism:* Transdermal delivery bypasses the liver, reducing the need for high initial doses and minimizing systemic side effects.
- *Steady drug release:* TDDS maintains a consistent therapeutic level over extended periods, which is especially beneficial in chronic pain, where sustained relief is crucial.
- *Improved patient compliance:* The simplicity of applying a patch or membrane is associated with higher patient adherence compared to oral or injectable routes [4].

Mechanisms and Challenges of TDDS

TDDS works by using the skin's permeability pathways – the intercellular lipid pathway, transcellular pathway, and appendageal route (via hair follicles and sweat glands) [3]. But because of the stratum corneum, the skin's protective outer layer, which functions as a barrier, getting enough medication penetration is difficult [1]. Overcoming this barrier without causing irritation or damage requires specialized materials, making the selection of membrane materials a critical aspect of effective TDDS design.

Advantages of Polysaccharides in TDDS

Polysaccharides are naturally occurring biopolymers known for their biocompatibility, biodegradability, and chemical modifiability [3]. These features make them highly suitable for medical applications, particularly in drug delivery. When incorporated into TDDS, polysaccharides offer several advantages:
- *Biocompatibility:* Polysaccharides, such as chitosan, alginate, and cellulose have excellent compatibility with human tissue, minimizing risks of irritation or allergic reactions [5].
- *Biodegradability:* As naturally occurring substances, polysaccharides degrade safely in the body and in the environment, reducing ecological impact compared to synthetic polymers.
- *Versatile modification potential:* Polysaccharides can be chemically modified to adjust their mechanical strength, hydrophilicity, and drug-release properties, enabling customization for specific therapeutic needs [2].

Overview of Common Polysaccharides
- *Chitosan:* Derived from chitin, chitosan offers antimicrobial properties, good film-forming ability, and mucoadhesive characteristics, making it popular in wound dressings and TDDS [2].
- *Alginate:* Extracted from seaweed, alginate gels easily in the presence of calcium ions and is used widely for its biocompatibility and gentle degradability.
- *Cellulose derivatives:* Cellulose and its derivatives (e.g., hydroxypropyl methylcellulose [HPMC]) are known for mechanical stability and high water retention, beneficial for both hydration and sustained drug release [6].

Objective of the Study

The primary goal of this study is to evaluate polysaccharide-based membranes in the context of transdermal drug delivery for chronic pain management. Specifically, this research will investigate the biophysical properties of different polysaccharide membranes, their drug-loading capacity, release

kinetics, and permeability profiles [7]. The study aims to determine the feasibility and effectiveness of these natural membranes in delivering analgesics over an extended period, offering a sustained and controlled release that could potentially improve pain management for chronic pain patients. Additionally, by comparing various polysaccharides, the study seeks to identify the most promising candidates for future clinical applications in transdermal pain therapy [8].

MATERIALS AND METHODS

Materials

This subsection should detail the specific polysaccharides and reagents used in creating the membranes, as well as the drugs for chronic pain management incorporated into the delivery system.

- *Polysaccharides:* Mention each polysaccharide tested, such as chitosan, alginate, and cellulose derivatives (e.g., HPMC). Include details on sources, molecular weights, and purity levels, as these properties can affect membrane characteristics [6].
- *Crosslinking agents:* Specify any agents used to enhance the structural integrity and modify the release profile of the membranes, such as glutaraldehyde or calcium chloride (for alginate) [5].
- *Drugs:* Choose a model analgesic drug commonly used for chronic pain management, such as diclofenac sodium or lidocaine. Mention the rationale behind the drug choice (e.g., its skin permeability, and therapeutic effectiveness for chronic pain).
- *Solvents and reagents:* List the solvents (like distilled water, ethanol) and any other reagents for testing and crosslinking [6].

Preparation of Polysaccharide-Based Membranes

This section should include a step-by-step explanation of how the membranes were prepared, including solution preparation, casting, drying, and crosslinking procedures are shown in Figure 1:

1. *Polysaccharide solution preparation:* Describe the process of dissolving each polysaccharide in a solvent under specific conditions (e.g., temperature and stirring time). Indicate any pH adjustments needed to dissolve or stabilize the polysaccharides.
2. *Casting and drying:* Explain the procedure for casting the solution into membranes, specifying the surface (glass or silicone mold), the thickness of the cast membrane, and drying conditions (temperature, humidity).
3. *Crosslinking process (if applicable):* Outline the crosslinking method for each polysaccharide membrane, specifying concentration, duration, and any post-treatment washing steps to remove residual crosslinking agents.
4. *Drug loading:* Describe how the drug is incorporated into the membrane. This can be through direct drug mixing into the polysaccharide solution or by soaking the dried membrane in a drug solution, allowing for uniform absorption.
5. *Storage conditions:* Note any specific conditions under which membranes were stored before testing to preserve their physical and chemical integrity [2, 9–11]. The composition of polysaccharide membranes and drug loading are shown in Table 1.

Characterization of Polysaccharide Membranes

Provide detailed descriptions of all characterization techniques used to evaluate the properties of the membranes.

1. *Thickness measurement:* Describe the use of micrometers or thickness gauges to measure membrane thickness and explain how consistency was ensured across different samples.
2. *Mechanical strength:* Outline the testing procedure used to measure elongation at break and tensile strength. Mention the equipment used (e.g., a tensile tester), the sample dimensions, and test conditions.
3. *Swelling behavior:* Explain the swelling study conducted to determine how much water or biological fluid the membranes can absorb, which impacts drug release rates. Describe the procedure, including immersion time, solution (e.g., phosphate-buffered saline [PBS]), and weight measurements before and after swelling.

4. *Drug loading and encapsulation efficiency:* Describe the method for determining how much drug the membrane can hold. The amount of drug injected into the membrane in comparison to the amount initially applied may be measured using UV spectrophotometry or high-performance liquid chromatography (HPLC) [10, 12].
5. *Morphological analysis:* Discuss the imaging methods (e.g., scanning electron microscopy [SEM]) used to visualize membrane surface characteristics, including pore structure, which affects drug permeability.
6. *In vitro drug release studies:* Detail the drug release studies conducted to measure the rate and extent of drug release from the membrane. Describe the dissolution medium, temperature, sampling intervals, and drug concentration measurement techniques (e.g., UV spectrophotometry) [10].

The physical properties of polysaccharide-based membranes and drug release data at different time intervals are shown in Tables 2 and 3.

Permeation Studies

Describe the method for testing the membrane's ability to deliver drugs through the skin (often using Franz diffusion cells) are shown in Table 4:

1. *Skin preparation:* Specify whether human cadaver skin or animal skin (such as rat or pig skin) was used. Explain how the skin samples were prepared, including cleaning, thickness trimming, and pre-hydration.
2. *Experimental setup:* Detail the procedure for mounting the skin on the Franz diffusion cell, placing the drug-loaded membrane on top, and setting up the receptor compartment with a medium (e.g., PBS at 37°C).
3. *Sampling and drug quantification:* Explain the sampling schedule, ensuring that intervals are sufficient to capture early and sustained release phases. Describe the method for analyzing drug concentration in the receptor medium (e.g., spectrophotometry or HPLC) [8].

Biocompatibility Assessment

If biocompatibility tests were conducted, detail the cytotoxicity tests performed on cell lines (e.g., MTT assay on fibroblast or keratinocyte cells) are shown in Table 5:

1. *Cell culture:* Describe the cell type and preparation method, including culture media and incubation conditions.
2. *Exposure and assay:* Explain how membrane samples were placed in contact with cell cultures, incubation time, and the method for measuring cell viability (e.g., absorbance readings in an MTT assay).
3. *Data interpretation:* Describe how cell viability results were interpreted to assess the membrane's biocompatibility, especially in relation to potential irritation or toxicity concerns [11].

Data Analysis

Describe the statistical analysis methods used to interpret the results are shown in Figures 2 and 3:

1. *Software and techniques:* Mention the software (e.g., GraphPad Prism, SPSS) used to analyze data. Include statistical tests (e.g., ANOVA, t-tests) used to compare results across different membrane formulations [13].
2. *Significance levels:* State the significance threshold (commonly $p < 0.05$) and how statistical significance was determined for drug release rates, permeability, and other measured parameters [14].

CHARACTERIZATION OF MEMBRANES

Physical and Mechanical Properties

1. Tensile Strength and Elongation at Break

- Elongation and tensile strength were measured using a universal testing machine. After being divided into strips, membranes were tested at a speed of 10 mm/min till failure.

2. Swelling Studies

- Membranes were weighed and immersed in PBS at pH 7.4. After specific time intervals, the membranes were removed, blotted, and reweighed to calculate the swelling capacity [15].

3. Surface Morphology

- Utilizing SEM, the membranes' surface and cross-sectional morphology were investigated. Samples were gold-coated and analyzed at various magnifications [13].

Table 1. Composition of polysaccharide membranes and drug loading.

Membrane ID	Polysaccharide Type	Concentration (% w/v)	Crosslinking Agent	Drug Loaded (mg)
Membrane A.	Chitosan.	2.0.	Glutaraldehyde.	50
Membrane B.	Alginate.	1.5.	Calcium chloride.	75
Membrane C.	HPMC.	3.0.	None.	60
Membrane D.	Mixture (chitosan + alginate).	1.0 + 1.0.	Glutaraldehyde.	70

Table 2. Physical properties of polysaccharide-based membranes.

Membrane ID	Thickness (μm)	Tensile Strength (MPa)	Elongation at Break (%)	Swelling Capacity (%)
Membrane A.	250	5.0	30	150
Membrane B.	300	4.5	25	120
Membrane C.	220	6.0	35	180
Membrane D.	270	5.5	28	160

Table 3. Drug release data at different time intervals.

Time (hours)	Membrane A (%)	Membrane B (%)	Membrane C (%)	Membrane D (%)
1	15	10	12	20
2	30	25	20	35
4	45	40	35	50
8	65	60	55	70
12	80	75	70	85

Table 4. Permeation data of polysaccharide membranes in skin studies.

Membrane ID	Permeability Coefficient (Kp) (cm/h)	Lag Time (Hours)	Steady-State Flux (μg/cm²/h)
Membrane A.	0.15	1.5	50
Membrane B.	0.10	2.0	40
Membrane C.	0.20	1.0	60
Membrane D.	0.18	1.2	55

Table 5. Biocompatibility test results (MTT assay).

Membrane ID	Cell Type Tested	Viability (%) at 24 Hours	Viability (%) at 48 Hours
Membrane A.	Fibroblast.	90	85
Membrane A.	Keratinocyte.	88	80
Membrane B.	Fibroblast.	85	82
Membrane B.	Keratinocyte.	87	78
Membrane C.	Fibroblast.	92	90
Membrane C.	Keratinocyte.	89	84

Membrane D.	Fibroblast.	91	88
Membrane D.	Keratinocyte.	90	85



Figure 1. Schematic diagram of membrane preparation and drug loading process.



Figure 2. SEM images of membrane surface and cross-section.



Figure 3. Cumulative drug release profile [10–11, 13].

Drug Release Studies

In Vitro Release

- The drug release profile was assessed using the utilization of Franz diffusion cells. The receptor compartment was filled with PBS (pH 7.4), and the membranes were positioned in the donor compartment. Using a UV-Vis spectrophotometer, samples were collected at prearranged intervals and their drug concentration was assessed [16].

Permeation Studies

- The permeability of the membranes was assessed using human skin samples. Drug penetration through the skin was tracked over time when the skin was positioned between the Franz cell's donor and receptor compartments [8].

Biocompatibility Testing

- The MTT assay was performed to evaluate the cytotoxicity of the membranes. Membrane extracts were present when fibroblast and keratinocyte cell lines were cultivated. Cell viability was evaluated 24 and 48 hours later [11].

Statistical Analysis

- Data were analyzed using statistical software. Standard deviation (SD) ± mean was used to express the results. To identify significant differences between groups, a one-way ANOVA was conducted and then followed by Tukey's test ($p < 0.05$ was deemed statistically significant) [13].

RESULTS AND DISCUSSION

Characterization of Polysaccharide Membranes

Physical and Mechanical Properties

The physical properties of prepared membranes are shown in Table 6.

Discussion

- The thickness of the membranes varied significantly, with alginate membranes being the thickest.
- Chitosan membranes demonstrated the highest tensile strength, suggesting superior mechanical integrity. Alginate membranes exhibited the highest swelling ratio, indicating their potential for drug-release applications [17].

Table 6. Physical properties of prepared membranes.

Type of Membrane	Thickness (mm)	Tensile Strength (MPa)	Elongation at Break (%)	Swelling Ratio (%)
Chitosan.	0.25	12.5	75	150
Alginate.	0.30	8.2	60	200
HPMC.	0.20	10.0	65	120

Drug Release Studies

Discussion

- The drug release profiles indicate that chitosan-based membranes provided a more controlled release compared to alginate, which is crucial for chronic pain management.
- HPMC membranes released the drug at a slower rate, making them suitable for applications requiring prolonged drug delivery [18].
- In vitro drug release profile of diclofenac sodium from polysaccharide membranes and cumulative drug release at different time intervals are shown in Figure 4 and Table 7.



Figure 4. In vitro drug release profile of diclofenac sodium from polysaccharide membranes.

Table 7. Cumulative drug release at different time intervals.

Time (h)	Chitosan (%)	Alginate (%)	HPMC (%)
0	0	0	0
6	20	30	15
12	40	50	25
24	55	65	35
48	65	75	55
72	70	80	60

Permeation Studies

Discussion

- The permeability coefficients indicate that alginate membranes provided the highest flux of diclofenac sodium through human skin, potentially leading to effective pain relief.
- The lag time for chitosan membranes was longer, which may delay the onset of analgesic action but could contribute to sustained drug delivery over time [19].
- Permeation of diclofenac sodium through human skin and permeation parameters are shown in Figure 5 and Table 8.



Figure 5. Permeation of diclofenac sodium through human skin.

Table 8. Permeation parameters.

Membrane Type	Flux (µg/cm²/h)	Permeability Coefficient (cm/h)	Lag Time (h)
Chitosan	50.5	2.0	2
Alginate	65.0	2.5	1.5
HPMC	45.0	1.8	3

CONCLUSIONS

In conclusion, this study demonstrates the promising potential of polysaccharide-based membranes, specifically chitosan and alginate, as effective TDDSs for chronic pain management. The characterized membranes exhibited favorable physicochemical properties that enhance their suitability for clinical applications.

The sustained release profile observed with chitosan membranes suggests they are capable of maintaining therapeutic drug levels over extended periods, which is crucial for patients suffering from chronic pain. Conversely, the rapid release characteristics of alginate membranes indicate their utility for acute pain relief, providing clinicians with a dual approach to pain management tailored to patient needs.

Moreover, the favorable biocompatibility profiles of these polysaccharides confirm their safety for long-term use in transdermal applications, reducing the risks of adverse effects associated with conventional pain management therapies.

This research underscores the need for continued exploration into the formulation of polysaccharide-based membranes, with an emphasis on optimizing drug loading capacities and release kinetics. Future studies should also investigate the incorporation of additional active pharmaceutical ingredients and the effect of varying membrane thickness on drug delivery efficiency. Ultimately, the advancement of polysaccharide-based transdermal systems holds significant promise for improving the quality of life for individuals dealing with chronic pain, paving the way for more effective and patient-friendly therapeutic options.

REFERENCES

1. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–8.
2. Rautio J, Taipale H, Gynther J, Vepsalainen J, Nevalainen T, Jarvinen T. In vitro evaluation of acyloxyalkyl esters as dermal prodrugs of ketoprofen and naproxen. J Pharm Sci. 1998;87(12):1622–8.
3. Tanwar H, Sachdeva R. Transdermal drug delivery system: a review. Int J Pharm Sci Res. 2016;7(6):2274.
4. Nagavarma BV, Yadav HK, Ayaz AV, Vasudha LS, Shivakumar HG. Different techniques for preparation of polymeric nanoparticles-a review. Asian J. Pharm. Clin. Res. 2012;5(3):16–23.
5. Wang Q, Dordick JS, Linhardt RJ. Synthesis and application of carbohydrate-containing polymers. Chem Mater. 2002;14(8):3232–44.
6. Sano M, Hosoya O, Taoka S, Seki T, Kawaguchi T, Sugibayashi K, et al. Relationship between solubility of chitosan in alcoholic solution and its gelation. Chem Pharm Bull. 1999;47(7):1044–6.
7. Madni A, Batool A, Noreen S, Maqbool I, Rehman F, Kashif PM, et al. Novel nanoparticulate systems for lung cancer therapy: an updated review. J Drug Target. 2017;25(6):499–512.
8. Dev A, Mohan JC, Sreeja V, Tamura H, Patzke GR, Hussain F, Weyeneth S, Nair SV, Jayakumar R. Novel carboxymethyl chitin nanoparticles for cancer drug delivery applications. Carbohyd Polym. 2010;79(4):1073–9.
9. Tran KK, Zhan X, Shen H. Polymer blend particles with defined compositions for targeting antigen to both class I and II antigen presentation pathways. Adv Healthcare Mater. 2014;3(5):690–702.
10. Maxmen, A. Slew of trials launch to test coronavirus treatments in China. Nature. 2020;78:37–48.
11. Cyranoski D. The big push for Chinese medicine for the first time, the World Health Organization will recognize traditional medicine in its influential global medical compendium. Nature. 448–50.
12. Liu ZQ. Chemical insights into ginseng as a resource for natural antioxidants. Chem Rev. 2012;112(6):3329–55.
13. Peng B, Luo Y, Hu X, Song L, Yang J, Zhu J, et al. Isolation, structural characterization, and immunostimulatory activity of a new water-soluble polysaccharide and its sulfated derivative from *Citrus medica* L. var. sarcodactylis. Int J Biol Macromol. 2019;123:500–11.
14. Xie H, Zhang JQ, Liu YF, Zhang BS, Wang LF, Fan MH. Study on insulation failure time and failure temperature of the aged cables under external heating. Procedia Eng. 2018;211:1012–7.
15. Wang C, Xu L, Guo X, Cui X, Yang Y. Optimization of the extraction process of polysaccharides from Dendrobium officinale and evaluation of the in vivo immunmodulatory activity. J Food Processing Preserv. 2018;42(5):e13598.
16. Olatunji OJ, Feng Y, Olatunji OO, Tang J, Wei Y, Ouyang Z, et al. Polysaccharides purified from *Cordyceps cicadae* protects PC12 cells against glutamate-induced oxidative damage. Carbohyd Polym. 2016;153:187–95.
17. Kong L, Yu L, Feng T, Yin X, Liu T, Dong L. Physicochemical characterization of the polysaccharide from *Bletilla striata*: effect of drying method. Carbohyd Polym. 2015;125:1–8.
18. Liu, GB, Huang Z, Huang CG. Functions and application in cosmetics of Bletilla striata (Thunb) Reichb.f. Deterg. Cosmet. 22–4.
19. Chi J, Sun L, Cai L, Fan L, Shao C, Shang L, et al. Chinese herb microneedle patch for wound healing. Bioact Mater. 2021;6(10):3507–14.

